# Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children

> **NCT01006629** · PHASE2,PHASE3 · COMPLETED · sponsor: **Abbott** · enrollment: 100 (actual)

## Conditions studied

- Respiratory Syncytial Virus Infection
- Premature Birth
- Bronchopulmonary Dysplasia
- Congenital Heart Disease

## Interventions

- **BIOLOGICAL:** palivizumab

## Key facts

- **NCT ID:** NCT01006629
- **Lead sponsor:** Abbott
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2010-04
- **Final completion:** 2010-07
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2011-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01006629

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01006629, "Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01006629. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*